- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460807
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT)
EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT
In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in patients with hormone-receptor-positive high grade serous or endometrioid Epithelian Ovarian Cancer (EOC). The patients enrolled in the EXPERT trial will receive exemestane or placebo in addition to standard treatment. Patients and investigators will be blinded to study treatment.
The hypothesis underlying the proposed clinical trial is that exemestane added to standard first line therapy will significantly prolong median progression free survival (PFS).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Estrogen and Progesterone play a role in promoting EOC growth, metastasis, and progression. Recent data show that ER and PgR expression is frequent in high grade EOC and has prognostic significance. A large meta-analysis showed a clinical benefit with any endocrine treatment, and in particular for aromatase inhibitors (AIs), with a greatere benefit for ER+ and/or PgR+ patients and platinum sensitive tumors. Moreover, the analysis of a few randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy in EOC, suggesting that ER and PgR have a predictive role and that inhibition of their activation could therefore be a treatment option for EOC.
Exemestane is a well-tolerated and effective AI in endocrine sensitive breast cancer which inhibits the production of Estrogens by the adipose tissue in postmenopausal women.
In this Italian, multicentre, randomized, double-blind, placebo controlled, phase III study will be assessed the efficacy of exemestane versus placebo in addition to the standard front line treatment in patients with high grade serous or endometrioid EOC, IHC positive (≥ 10%) ER or PgR disease, stage IIB - IV according to the FIGO classification.
The primary objective of the study is to test the superiority of exemestane over placebo in addition to the standard front line treatment in terms of PFS.
Secondary Objectives are:
- to test whether the percent expression of ER and PgR is predictive of the effect of exemestane on PFS;
- to test whether the addition of exemestane to the standard front line treatment can prolong Overall Survival (OS);
- to evaluate objective response rate Overall Response Rate (ORR) of experimental treatment compared with the standard one;
- to assess whether the effect of exemestane is affected by the proliferative index Ki67;
- to evaluate the effect of exemestane on Quality of Life (QoL);
- to evaluate the compliance to the study treatment;
- to evaluate the safety profile of the experimental treatment compared with the standard one.
Study design: a total of 468 subjects (234 per Arm) will be randomized in a 1:1 ratio to receive either standard chemotherapy treatment plus exemestane (Experimental arm) or standard chemotherapy plus placebo (Control arm). Exemestane/placebo will be self-administered as a single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first. Radiological disease assessments and CA125 will be performed at baseline and every 4 months from randomization, until end of study or disease progression whichever comes first. Safety assessments will be performed at each cycle during standard chemotherapy treatment, then at each study visit, up to 30 days after the last Experimental Treatment administration.Quality of Life will be assessed by a menopause-specific questionnaire, administered to patients at baseline (T0), at 12 months (T1) and at disease progression (T2). For patients who have signed the specific informed consent, tissues and blood samples will be collected.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Alessandra Argusti
- Phone Number: 00390105634188
- Email: alessandra.argusti@galliera.it
Study Contact Backup
- Name: Silvia Caviglia
- Phone Number: 00390105634234
- Email: silvia.caviglia@galliera.it
Study Locations
-
-
-
Genova, Italy, 16128
- Medical Oncology Division, Ente Ospedaliero Ospedali Galliera
-
Napoli, Italy
- Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale"
-
Novara, Italy
- Azienda Ospedaliero-Universitaria Maggiore della Carità
-
-
AL
-
Alessandria, AL, Italy
- AO SS Antonio e Biagio e Cesare Arrigo
-
-
BA
-
Bari, BA, Italy
- Ospedale Oncologico IRCCS Bari
-
-
BI
-
Biella, BI, Italy
- Ospedale degli Infermi
-
-
BL
-
Feltre, BL, Italy
- AULSS 1 Dolomiti - Ospedale "Santa Maria del Prato"
-
-
BO
-
Bologna, BO, Italy
- Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi
-
-
BS
-
Brescia, BS, Italy
- Fondazione Poliambulanza
-
Brescia, BS, Italy
- Asst Degli Spedali Civili Di Brescia
-
Manerbio, BS, Italy
- Ospedale di Manerbio
-
-
CA
-
Cagliari, CA, Italy
- AOU Cagliari, Policlinico Universitario
-
-
CH
-
Chieti, CH, Italy
- Ospedale Policlinico "SS. Annunziata"
-
-
CN
-
Alba, CN, Italy
- Azienda Sanitaria Locale CN2
-
Cuneo, CN, Italy
- Azienda Ospedaliera S.Croce e Carle
-
Mondovì, CN, Italy
- Ospedale di Mondovì CN1
-
-
CO
-
Como, CO, Italy
- Ospedale Sant Anna di Como
-
-
CT
-
Catania, CT, Italy
- ARNAS Garibaldi
-
Catania, CT, Italy
- Azienda Ospedaliera per l'emergenza Cannizzaro
-
-
FC
-
Meldola, FC, Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
-
-
FG
-
San Giovanni Rotondo, FG, Italy
- Ospedale Casa Sollievo della Sofferenza
-
-
GE
-
Genova, GE, Italy
- ASL 3 Ospedale Villa Scassi
-
Genova, GE, Italy
- IRCCS AOU San Martino - IST
-
-
LC
-
Lecco, LC, Italy
- ASST Lecco - Ospedale "A. Manzoni"
-
-
LE
-
Lecce, LE, Italy
- Ospedale "Vito Fazzi"
-
-
MB
-
Monza, MB, Italy
- UOS Oncologia Ginecologica, Ospedale S. Gerardo
-
-
MC
-
Macerata, MC, Italy
- Presidio Ospedaliero Unico Av3
-
-
MI
-
Milano, MI, Italy
- Istituto Europeo di Oncologia (IEO)
-
-
MO
-
Modena, MO, Italy
- AOU Policlinico di Modena
-
-
PA
-
Palermo, PA, Italy
- A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli
-
-
PC
-
Piacenza, PC, Italy
- Ospedale "Guglielmo da Saliceto"
-
-
PI
-
Pisa, PI, Italy
- Azienda Ospedaliero-Universitaria Pisana
-
-
PN
-
Aviano, PN, Italy
- CRO Centro di Riferimento Oncologico
-
-
PV
-
Pavia, PV, Italy
- Fondazione IRCCS Policlinico San Matteo
-
-
PZ
-
Potenza, PZ, Italy
- Azienda Ospedaliera Regionale San Carlo
-
-
RA
-
Faenza, RA, Italy
- Ospedale "degli Infermi"
-
Lugo, RA, Italy
- Ospedale "Umberto I"
-
Ravenna, RA, Italy
- Ospedale Santa Maria delle Croci
-
-
RE
-
Reggio Emilia, RE, Italy
- Azienda Ospedaliera Arcispedale Santa Maria Nuova
-
-
RM
-
Roma, RM, Italy
- Policlinico Umberto I, Università di Roma "La Sapienza"
-
Roma, RM, Italy
- Policlinico Universitario Fondazione Agostino Gemelli
-
-
SO
-
Sondrio, SO, Italy
- ASST Valtellina e Alto Lario
-
-
SS
-
Sassari, SS, Italy
- Azienda Ospedaliero Universitaria di Sassari
-
-
TO
-
Candiolo, TO, Italy
- Fondazione del Piemonte per l'Oncologia - IRCCS
-
Torino, TO, Italy
- AO Ordine Mauriziano
-
Torino, TO, Italy
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza - Ospedale Ostetrico Ginecologico Sant'Anna
-
-
VC
-
Vercelli, VC, Italy
- Presidio Ospedaliero S. Andrea
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Citologically or histologically confirmed high grade serous or endometrial epithelial ovarian cancer, including cancer of fallopian tube and peritoneum. For patients who are candidates for neoadjuvant chemotherapy, diagnosis must be documented via imaging or a core tissue (not fine needle aspiration) biopsy.
- Disease stage IIB to IV according to FIGO classification. For patients who are candidates for neoadjuvant chemotherapy, stage IIB-IV should be documented via imaging or a core tissue (not fine needle aspiration) biopsy.
- Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy. For patients enrolling after debulking surgery, randomization should occur at a maximum of 12 weeks and not before 4 weeks after surgery.
- Immunoistochemically determined positivity (≥ 10%) for Progesterone and/or Estrogen receptor expression, including determination on cytology smears from ascitic fluid if surgery is differed.
- Measurable or evaluable disease confirmed by radiological imaging, or histological proven ovarian cancer in the absence of postoperatively measurable or evaluable lesions
- Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0-2.
- Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
- Previous systemic therapy for ovarian cancer.
- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
- Inadequate bone marrow, hepatic or renal functions, assessed within 7 days prior to randomization.
- Treatment with hormonal contraceptives during the previous 3 months from diagnosis.
- Concurrent comorbidities, which contraindicates the administration of chemotherapy, or endocrine therapy.
- Pregnant or lactating patients.
- Inability or unwillingness to swallow tablets.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exemestane
Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery. + Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first. |
Exemestane in addition to standard therapy, in Experimental arm.
Other Names:
|
Placebo Comparator: Placebo
Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery. + Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first. |
Placebo in addition to standard therapy, in Control arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Up to 20 months
|
PFS id defined for each patient as the time from the date of randomization to the date of local or regional relapse, distant metastasis, second primary malignancy or death from any cause, whichever comes first.
Patients not recurred, progressed or died while on study or lost to follow-up will be censored at their last disease assessment date.
|
Up to 20 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to 20 months
|
OS is defined for each patient as the time from the date of randomization to the date of death from any cause.
Patients not reported as having died at the end of the study will be censored at the date they were last known to be alive.
|
Up to 20 months
|
Objective Response Rate (ORR)
Time Frame: a CT-scan will be performed every 4 months. Up to 20 months from last patients randomized
|
ORR is defined as the number of patients who will experience a complete or partial response divided by the number of patients randomized with at least one target lesion at baseline.
Each patient will be assigned the best response ever recorded during the trial
|
a CT-scan will be performed every 4 months. Up to 20 months from last patients randomized
|
Quality of Life: Menopause Quality of Life (MENQoL) questionnaire
Time Frame: Up to 20 months
|
The effect of study treatment will be assessed based on the MENQOL intervention questionnaire based on 29 items divided in four domains (vasomotor, physical, psychosocial and sexual), each scored from 1 to 8 (1 means no symptom, 2 presence of the symptoms but not bothersome, 3-8 an increasing grade of discomfort).
Mean changes from the baseline domain scores between treatment arms will be evaluated.
|
Up to 20 months
|
Compliance - Number of administered cycles
Time Frame: Up to 20 months
|
Number of administered cycles
|
Up to 20 months
|
Compliance - Reasons for discontinuation and treatment modification
Time Frame: Up to 20 months
|
Number of patients for each reasons
|
Up to 20 months
|
Compliance - Dose intensity
Time Frame: Up to 20 months
|
Number of tablets taken (i.e., number of tablets given-number of tablets returned)/number of tablets that should have been taken during the treatment period.
|
Up to 20 months
|
Safety (Adverse Events)
Time Frame: Up to 20 months
|
Maximum toxicity grade experienced by each patient for each toxicity, proportion of patients experiencing grade 3-4 toxicity for each toxicity, type, frequency and nature of serious adverse events (SAEs).
|
Up to 20 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Circulating and tissue biomarkers
Time Frame: Up to 20 months
|
To collect and store blood and tissue samples to create a bio-bank for the assessment of circulating and tissue biomarkers with potentially prognostic/predictive value, including the androgen receptor (AR) expression and the generation of a somatic genomic and transcriptomic atlas of epithelial ovarian cancers, to map the different molecular vulnerabilities lagging behind the single definition of each histological subtype. Data generated will allow to select molecular biomarkers with prognostic/predictive relevance, to have information of patients risk of relapse or to guide novel treatment approaches. These biomarker endpoints will be considered in a second phase of the study, if additional funds are available to perform the analyses. |
Up to 20 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrea DeCensi, E.O. Ospedali Galliera Genova
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Exemestane
Other Study ID Numbers
- 56UCS2017
- 2018-000693-30 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
Clinical Trials on Exemestane
-
Actavis Inc.Withdrawn
-
Jules Bordet InstituteNovartisCompleted
-
PfizerTerminated
-
PfizerCompletedPost Menopausal Women With Early Breast Cancer
-
Bristol-Myers SquibbCompletedBreast CancerCzech Republic, United States, Spain, United Kingdom, Ireland, Poland, France, Sweden
-
Veru Inc.WithdrawnMetastatic Breast CancerUnited States
-
Dalin Tzu Chi General HospitalCompletedHearing ImpairmentTaiwan
-
NCIC Clinical Trials GroupUNICANCER; Grupo Espanol de Investigacion del Cancer de MamaCompletedBreast CancerUnited States, France, Canada, Puerto Rico
-
PfizerCompleted
-
Roxane LaboratoriesCompleted